E
Erik Änggård
Researcher at St Bartholomew's Hospital
Publications - 154
Citations - 12216
Erik Änggård is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Endothelium & Arachidonic acid. The author has an hindex of 58, co-authored 154 publications receiving 12055 citations. Previous affiliations of Erik Änggård include Karolinska Institutet & Umeå University.
Papers
More filters
Journal ArticleDOI
Regulatory functions of the vascular endothelium.
TL;DR: The vascular endothelium, which envelops the circulating blood in a continuous monolayer, is mainly responsible for this function, but over the past 20 years numerous other important functions have been discovered.
Journal ArticleDOI
Nitric oxide: mediator, murderer, and medicine
TL;DR: In the past ten years several research fields have converged to show that the tiny molecule nitric oxide (NO), a reactive gas, functions both as a signalling molecule in endothelial and nerve cells and as a killer molecule by activated immune cells as mentioned in this paper.
Journal ArticleDOI
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine.
TL;DR: The biosynthesis of endothelium-derived relaxing factor may, therefore, not only produce a powerful vasodilator but also relieve the endothelial cell of excess nitrogen.
Journal ArticleDOI
Plasma 8-epi-PGF2α levels are elevated in individuals with non-insulin dependent diabetes mellitus
Nitin K Gopaul,Erik Änggård,A.I. Mallet,D. J. Betteridge,Simon P. Wolff,Jaffar Nourooz-Zadeh +5 more
TL;DR: In this paper, the authors reported plasma levels of a specific nonenzymatic peroxidation product of arachidonic acid, esterified 8-epi-PGF2α, from healthy and NIDDM individuals as an index of oxidative stress in vivo.
Journal ArticleDOI
Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus.
Philip Chowienczyk,R P Kelly,R P Kelly,R P Kelly,Helen MacCallum,Helen MacCallum,Helen MacCallum,Sandrine Millasseau,Sandrine Millasseau,Sandrine Millasseau,Tomas Andersson,R. G. Gosling,R. G. Gosling,R. G. Gosling,James M. Ritter,James M. Ritter,James M. Ritter,Erik Änggård +17 more
TL;DR: The effects of albuterol on IP(DVP) are mediated in part through the nitric oxide pathway and are impaired in patients with type II diabetes.